Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 592-597, November 2009

Prognostic significance of prostate cancer originating from the transition zone

  • Christopher R. King, Ph.D., M.D.

      Affiliations

    • Department of Radiation Oncology, Division of Urologic Oncology; Stanford University School of Medicine, Stanford, CA 94305, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-650-736-0698; fax: +1-650-725-8231
  • ,
  • Michelle Ferrari, R.N.

      Affiliations

    • Department of Urology, Division of Urologic Oncology; Stanford University School of Medicine, Stanford, CA 94305, USA
  • ,
  • James D. Brooks, M.D.

      Affiliations

    • Department of Urology, Division of Urologic Oncology; Stanford University School of Medicine, Stanford, CA 94305, USA

Received 24 March 2008; received in revised form 16 May 2008; accepted 23 May 2008. published online 17 September 2008.

Abstract 

Purpose

Transition zone (TZ) cancers are reported to have better biochemical relapse-free survival (bRFS) after radical prostatectomy (RP) than cancers from the peripheral zone (PZ). To understand the influence of tumor location, we compared bRFS for TZ and PZ cancers stratified for risk using known clinical and pathological prognostic factors.

Patients and Methods

The surgical pathology and outcomes of 494 patients were reviewed. Cancers originating from the TZ and PZ were identified from step sectioning of surgical specimens and tumor mapping. Univariate and multivariate analyses of bRFS after RP were compared.

Results

TZ cancers were present in 89 (18%) patients. On univariate analysis, most factors predicted bRFS, although cancer location did not: 5-year bRFS was 85% for TZ vs. 77% for PZ (P = 0.12). However, on multivariate analysis, all factors except SV involvement were significant, including TZ cancer location (P = 0.04, HR = 1.88 [1.02–3.47]). Interestingly, TZ location was correlated with improved 5-year bRFS for cancers > 2 cc (81% for TZ vs. 65% for PZ, P = 0.017), for preop PSA >10 (80% for TZ vs. 59% for PZ, P = 0.027), and for PSAV > 2 (85% for TZ vs. 66% for PZ, P = 0.08). However, TZ cancers showed no difference in outcome for small volumes, low preop PSA, low PSAV, or high Gleason grade.

Conclusions

TZ cancers that are large, with high preop PSA, low Gleason scores, and high PSAV show better outcomes than their PZ counterparts. However, high-grade cancer tumor location had no apparent influence on outcome. Tumor location could be considered in subsets for optimal prognostication.

Keywords: Prostate cancer, Gleason grade, Biochemical relapse-free survival

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This research was supported in part by grants to J.D.B. from the National Institutes of Health grant CA111782, Stanford University Bio-X Interdisciplinary Initiatives Award and the Canary Foundation.

PII: S1078-1439(08)00123-3

doi:10.1016/j.urolonc.2008.05.009

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 592-597, November 2009